Cleared Traditional

FLUOBEAM LX Imaging System (FBLX) (K250455) - FDA 510(k) Clearance

Also marketed or referenced as:
FLUOBEAM LM Imaging System (FBLM)

Class II General & Plastic Surgery device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K250455 · Fluoptics Sas (A Getinge Group Company) · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2025
Decision
58d
Days
Class 2
Risk

K250455 is an FDA 510(k) clearance for the FLUOBEAM LX Imaging System (FBLX). Classified as Parathyroid Autofluorescence Imaging Device (product code QDG), Class II - Special Controls.

Submitted by Fluoptics Sas (A Getinge Group Company) (Grenoble, FR). The FDA issued a Cleared decision on April 17, 2025 after a review of 58 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4550 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Fluoptics Sas (A Getinge Group Company) devices

Submission Details

510(k) Number K250455 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 18, 2025
Decision Date April 17, 2025
Days to Decision 58 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
57d faster than avg
Panel avg: 115d · This submission: 58d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code QDG Parathyroid Autofluorescence Imaging Device
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 878.4550
Definition An Autofluorescence Detection Device For General Surgery And Dermatological Use Is An Adjunct Tool That Uses Autofluorescence To Detect Tissues Or Structures. This Device Is Not Intended To Provide A Diagnosis.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General & Plastic Surgery devices follow this clearance model.

Regulatory Consultant

Getinge Group
Barb Smith

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - QDG Parathyroid Autofluorescence Imaging Device

Devices cleared under the same product code (QDG) and FDA review panel - the closest regulatory comparables to K250455.
Dendrite Imaging System
K253303 · Dendrite Imaging, Inc. · Nov 2025
FLUOBEAM® LX Imaging System (FB-LX)
K233564 · Fluoptics Sas (A Getinge Group Company) · Dec 2023
FLUOBEAM® LX Red
K230898 · Fluoptics Sas · Jul 2023
Fluobeam LX
K190891 · Fluoptics · Jul 2019
Fluobeam 800 Clinic Imaging Device used with Fluocase 800 Control System
DEN170092 · Fluoptics · Nov 2018